A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial.Blood advances · 2023
   Trial
2. Cereblon expression is a prognostic marker in newly diagnosed POEMS syndrome treated with lenalidomide plus dexamethasone.Annals of hematology · 2021
   Trial
3. Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.Scientific reports · 2019
   Trial
4. Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.BJU international · 2016
   Trial
5. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.Leukemia · 2016
   Trial
6. Lower-risk myelodysplastic syndromes: Current treatment options for anemia.EJHaem · 2022
   Review
7. Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.International journal of molecular sciences · 2020
   Article
8. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.Frontiers in immunology · 2018
   Article
9. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.Leukemia · 2016
   Article
10. [Long- term outcome of thalidomide and cyclosporine in patients with IPSS low/intermediate- 1 myelodysplastic syndromes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015
    Article
11. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.Journal of blood medicine · 2015
    Review
12. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.Leukemia · 2014
    Article
13. There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Current hematologic malignancy reports · 2013
    Review
14. Current therapy of myelodysplastic syndromes.Blood reviews · 2013
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as